Is taking probiotics during pregnancy safe?

Probiotic supplementation during pregnancy has a well-established safety record. Decades of clinical research have not identified serious adverse effects for mother or infant from common Lactobacillus and Bifidobacterium strains. Women with severely compromised immunity or certain medical conditions should discuss it with their provider, but for most healthy pregnant women the safety profile is favorable.

Which strains are most effective for atopic dermatitis prevention?

Lactobacillus strains, particularly Lactobacillus rhamnosus GG (LGG), have the most clinical evidence. The meta-analysis found Lactobacillus supplementation drove a 10.6% risk reduction, while Bifidobacterium strains showed no statistically significant difference. Multi-strain products may outperform single-strain, though the evidence base is smaller.

Should I continue after delivery?

Combining prenatal and postnatal supplementation produced the largest effect in the meta-analysis. The benefit extends through breastfeeding, as maternal microbiota reaches the infant through breast milk. Continuing for six to twelve months postpartum, and directly supplementing the infant, is the most studied approach for high-risk families.

Probiotics During Pregnancy Reduce Child's Atopic Dermatitis Risk by 10.6%

Atopic dermatitis affects 15 to 20 percent of children globally and causes substantial burden on quality of life for both the child and family. When parents carry a personal or family history of atopic dermatitis, asthma, or allergic rhinitis, the child’s risk is meaningfully elevated. Meta-analyses published in Translational Pediatrics and Frontiers in Nutrition now offer a quantified answer to whether maternal probiotic supplementation can change that trajectory.

The Numbers from the Meta-Analysis

Pooling data from multiple randomized controlled trials, the meta-analysis found that probiotic supplementation during pregnancy reduced the risk of atopic dermatitis in children aged 2-7 by 5.7%. When the analysis was restricted to Lactobacillus-specific strains, the risk reduction widened to 10.6%.

Translating these figures to practical terms: among 100 children in high-risk families, the intervention prevents atopic dermatitis in approximately 5 to 10 cases. The magnitude appears modest in isolation, but atopic dermatitis in early childhood is associated with disrupted sleep, behavioral difficulties, significant healthcare costs, and an increased trajectory toward the “atopic march,” the progression from eczema to asthma and allergic rhinitis.

How the Gut Programs the Immune System

The mechanism involves fetal immune programming during pregnancy. The fetal immune system is shaped by signals from the maternal environment, including microbial signals that pass through the placenta and amniotic fluid. Maternal gut microbiota composition influences cytokine profiles circulating in the fetal environment.

The core immune imbalance in atopic dermatitis is a Th2-skewed response, where allergic reaction pathways are disproportionately active relative to Th1-mediated responses. Lactobacillus strains stimulate Th1 immune activity, partially counterbalancing this skew before the infant’s immune system sets its baseline.

The birth process also contributes. Vaginal delivery exposes the infant to maternal microbiota, shaping early gut colonization. Research consistently finds slightly higher atopic dermatitis rates following cesarean delivery, likely reflecting differences in that initial microbial exposure.

Timing Matters: Prenatal Plus Postnatal Wins

The meta-analysis directly compared intervention timing. Combined prenatal and postnatal supplementation produced larger effect sizes than prenatal alone. The ongoing mechanism is breast milk: maternal gut bacteria transfer into breast milk, and breastfeeding shapes the infant’s developing microbiome over the first months of life. Postnatal probiotic supplementation of the mother, and direct supplementation of the infant, extends the window of microbiome influence.

Dose and Strain Selection

Clinical studies used doses in the range of 10 million to 30 billion CFU per day. Evidence points toward multi-strain formulations outperforming single-strain products in some comparisons, though the evidence base is smaller. Lactobacillus rhamnosus GG (LGG) holds the deepest individual strain evidence. Multi-strain combinations including LGG, Lactobacillus acidophilus, and Bifidobacterium longum are commonly used in commercial practice.

The World Allergy Organization (WAO) has incorporated this evidence into its guidelines, recommending probiotic supplementation for pregnant and breastfeeding women in high-risk families, as well as directly for at-risk infants. The distinction that WAO maintains is between prevention and treatment: the evidence is stronger for preventing atopic dermatitis before it develops than for treating established disease.

For families with atopic history, probiotics represent one of the few evidence-based prenatal decisions available before the infant’s immune baseline is set.

Source: Translational Pediatrics / Frontiers in Nutrition